Risk of hepatocellular carcinoma development in long-term nucles(t)ide analog suppressed patients with chronic hepatitis B

Abstract

Aim: In long-term nucleos(t)ide analog (NA) suppressed patients with chronic hepatitis B (CHB), hepatocellular carcinoma (HCC) can still develop. Few data exist on the incidence and the predictors of HCC development beyond the first five years in long-term treated patients. To assess the prevalence, incidence, and risk factors for HCC development in a real-life cohort of successfully NA-treated CHB patients for more than five years.

Methods: All CHB patients under NAs for ≥ 60 months with stable virologic response were enrolled. HCC surveillance was carried out using liver ultrasound and dosing of serum alpha-fetoprotein every year in patients with CHB and every six months in cirrhotic patients. The baseline PAGE-B score was calculated for each patient.

Results: 343 patients (76% male, 86% HBeAg-negative, 30% cirrhotic) were enrolled. During a median (IQR) follow-up of 144 (105-182) months, 21 patients (6%) developed HCC despite virologic suppression (incidence rate 40 cases/1000 person-years follow-up). In multivariate analysis, higher PAGE B score [adjusted Hazard Ratio, aHR 1.26 (95%CI: 1.13-1.54), P = .022] and cirrhosis [aHR 9.71 (95%CI: 2.02-46.48), P = .005] were predictors of HCC development. PAGE B score showed a significant association with HCC (R² 0.225, P < .001) and good prognostic capacity (AUC 0.863) of HCC.

Conclusions: Our results confirm that in successfully NA-treated CHB patients, sustained viral replication suppression does not abolish the risk of HCC. The PAGE-B score could be a useful tool for identifying high-risk subjects.

Keywords

Chronic hepatitis B / nucleos(t)ide analogs / hepatocellular carcinoma / PAGE-B score / entecavir / tenofovir disoproxil fumarate / tenofovir alafenamide

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[3] Association for the Study of the Liver; Electronic address: [e-mail]; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017;67:370-98

[4] Terrault NA,McMahon BJ.Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.Hepatology2018;67:1560-99

[5] Sarin SK,Lau GK.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016;10:1-98 PMCID:PMC4722087

[6] Papatheodoridis GV,Hansen BE,Lampertico P.Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.J Hepatol2015;62:956-67

[7] Papatheodoridis GV,Dalekos GN.The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.Hepatology2017;66:1444-53

[8] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[9] Colli A,Miletic D.Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.Cochrane Database Syst Rev2021;4:CD013346 PMCID:PMC8078581

[10] Wong VW,Mo F.Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.J Clin Oncol2010;28:1660-5

[11] Yang HI,Chan HL.REACH-B Working GroupRisk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.Lancet Oncol2011;12:568-74

[12] Wong GL,Wong CK.Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.J Hepatol2014;60:339-45

[13] Yuen MF,Fong DY.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.J Hepatol2009;50:80-8

[14] Shen Y,Han Z,Cui H.Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: a meta-analysis.Clin Res Hepatol Gastroenterol2022;46:101930

[15] Voulgaris T,Lampertico P.Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B.Liver Int2020;40:484-95

[16] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol2016;64:800-6

[17] Hsu YC,Ho HJ.Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.J Hepatol2018;69:278-85

[18] Kim JH,Lee M.Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.J Hepatol2018;69:1066-73

[19] Lee HW,Kim BK.Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy.Am J Gastroenterol2014;109:1241-9

[20] Sohn W,Kim JH.Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.Clin Mol Hepatol2017;23:170-8 PMCID:PMC5497662

[21] Yu JH,Jin YJ.Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.Eur J Gastroenterol Hepatol2019;31:865-72

[22] Chen CH,Lai HC.Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir.Oncotarget2017;8:92431-41 PMCID:PMC5696194